TC-G203 for adults with GPC3-positive advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is advanced and you have tried standard treatments without success.
- Your tumor has a specific protein called GPC3, confirmed by a lab test.
- You are in good enough health to participate (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You are not pregnant, breastfeeding, or using effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
This trial tests a new treatment called CAR-T cells that are designed to find and attack liver cancer cells with a specific marker (GPC3). If you have advanced hepatocellular carcinoma (liver cancer) that has not responded to standard treatments, this study may be an option to explore.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
Hear when a new Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.